Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has expanded its ai² Future Labs program to include graduate students from the University of San Diego’s Knauss School of Business. The initiative aims to identify promising pharmaceutical assets with the potential to significantly improve human health, while also developing the next generation of leaders in the biopharmaceutical sector. As part of Apimeds’ broader ai² innovation strategy, the program leverages academic talent to drive early-stage drug development and business planning. Through hands-on experience, students collaborate on real-world challenges in biotech commercialization, gaining exposure to drug discovery, market analysis, and strategic business development. The partnership underscores Apimeds’ commitment to fostering innovation through academic collaboration and building a pipeline of skilled professionals equipped to lead in the evolving healthcare landscape.